Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): a randomized, observer-blinded, placebo-controlled trial

Pengfei Jin, Xiling Guo, Wei Chen, Shihua Ma, Hongxing Pan, Lianpan Dai, Pan Du, Lili Wang, Lairun Jin, Yin Chen, Fengjuan Shi, Jingxian Liu, Xiaoyu Xu, Yanan Zhang, George F. Gao, Cancan Chen, Jialu Feng, Jingxin Li, Fengcai Zhu
doi: https://doi.org/10.1101/2022.02.24.22271445

Data Availability

All relevant data are within the manuscript and its Supporting Information files. Individual participant data will be available for request 1 month after the completion of the study (anticipated in April 2022), upon requests directed to the corresponding author(jszfc{at}vip.sina.com)

Back to top
Posted March 01, 2022.
Download PDF
Data/Code
Email
Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): a randomized, observer-blinded, placebo-controlled trial
Pengfei Jin, Xiling Guo, Wei Chen, Shihua Ma, Hongxing Pan, Lianpan Dai, Pan Du, Lili Wang, Lairun Jin, Yin Chen, Fengjuan Shi, Jingxian Liu, Xiaoyu Xu, Yanan Zhang, George F. Gao, Cancan Chen, Jialu Feng, Jingxin Li, Fengcai Zhu
medRxiv 2022.02.24.22271445; doi: https://doi.org/10.1101/2022.02.24.22271445
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area